Dr. Alexander GolBerg - Concierge and Aesthetic Medicine
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- IV Therapy
New York, NY
Chelation therapy in New York is offered by a small set of integrative and naturopathic clinics, typically for documented heavy metal toxicity. Referral and testing pathways often interact with NYU Langone, Mount Sinai, NewYork-Presbyterian, and Memorial Sloan Kettering when lab confirmation is needed. Local demand is shaped by a dense, diverse, and high-income patient base with strong demand for cash-pay specialty care, and clinics vary in whether they push short detox courses or longer TACT-modeled cardiovascular protocols.
FDA-approved agents for specific poisoning diagnoses include calcium disodium EDTA, DMSA, and deferoxamine. Chelation for cardiovascular disease or autism is not FDA-approved and has caused deaths when the wrong EDTA form is used. New York State Department of Health's strict scope-of-practice and supervision enforcement shapes which providers can deliver chelation and under what supervision.
With verified chelation clinics on Regenerated.com in New York, New York, patients can compare provider credentials, testing protocols, and whether the clinic uses calcium disodium EDTA (the correct form) or the dangerous disodium EDTA. ACAM-trained MDs with documented pre-treatment heavy metal testing are the minimum bar.
Regulatory context
The FDA has approved a narrow set of chelating agents for specific heavy metal toxicities. Calcium disodium edetate (CaNa2EDTA, Versenate) is approved for symptomatic lead poisoning, succimer (Chemet, DMSA) for pediatric lead poisoning at blood lead levels above 45 mcg/dL, deferoxamine (Desferal) and deferasirox (Exjade) for chronic iron overload, and dimercaprol (BAL) for arsenic, gold, and acute lead poisoning. Use of EDTA chelation for cardiovascular disease was studied in the NIH-funded TACT trial (2013) with controversial findings and remains not FDA-approved for that indication. Chelation for autism spectrum disorder is not evidence-based and has been linked to pediatric deaths. The FDA issued a 2010 sweep of warning letters to compounders marketing OTC chelation products with unapproved disease claims.
The New York State Office of Professional Medical Conduct (OPMC) has investigated chelation practitioners for marketing claims tied to autism and cardiovascular disease. New York does not license NDs. New York City and the surrounding areas have a large integrative medicine community. New York has historically been one of the more aggressive states on enforcement against off-label chelation marketing, particularly for pediatric autism. The 2005 Pittsburgh pediatric chelation death prompted heightened New York scrutiny.